1

THE EDITORIAL
Address,
He who has health has hope and he who has hope has
everything. The primary concern in this hectic life today is CONTENTS
health and more people are becoming health conscious.
With increasing level of awareness in this regard the
• Cover Story 3
masses do not have much time to visit a physician. This --“Cide” ing Side Effects
leads to more and more people catering in to the OTC
drugs which contribute a lot to the pharmaceutical sector. • Articles/Analysis 4
There are more than 100,000 drugs that fall in this category.
Owing to this we have decided to dedicate the August issue --Pack in your senses
of our monthly newsletter to Over the Counter medicines.
An extensive study has been carried out by the students to
• Back to Society 5
analyze the reasons for side effects of pain killers and --“SPARSH” Initiative by Torrent Group
suggesting ways to combat the same.
• BT News 6
We also bring to you an exclusive interview with Mr.
Madhukar Kurtkoti an eminent person from the --Going Green—The Patent Way
Pharmaceutical industry with over 35 years of experience
• Candid Talk 7
throwing light related to marketing of OTC.
--An Interview with Mr. Madhukar Kurtkoti
An article related to Packaging with respect to these drugs
is also included. • PUMBA News 8

In the BT news section we take upon the various aspects of --Dr. (Prof.) Sangvikar’s Selection for University Exchange
the Mashelkar’s report with respect to ever greening of Program
patents.
-- Dr.(Capt) C.M. Chitale appointment to “YASHADA”
We also present before you one of the 12 part series of
--Dr. S.V. Kapre’s Lecture
notable CSR initiatives. The article titled ‘Back to Society’
this time covers the SPARSH initiative by Torrent Group.
Along with this section on PUMBA and its latest happenings
has been included.

Your feedback and Suggestions are welcome at

thepumbagazette@gmail.com
“Reading maketh a full man, conference a ready man,
and writing an exact man” - Francis Bacon

Sincerely Yours,
Chief Editor: Queeny Bubna, MBA-BT (Sem III)
(The PUMBA Gazette Team)
(The detailed project report shall be provided on
enquiry. Kindly send in your enquiries at
thepumbagazette@gmail.com)

2
“Cide”ing side effects…
The over- the-counter and prescription painkillers also known as
the non-steroidal anti-inflammatory drugs or NSAIDs are one of
the most widespread used drugs. The number of over-the-counter
(OTC) medications is increasing as more prescription medications
are being designated the OTC status and there are over 100,000
such drugs. Despite their extensive use it is observed that it is
often used inappropriately and an alarming number of people are
ignorant of the potential side effects that result thereafter. So a
survey was carried out by the students of PUMBA to gauge the
awareness of side effects of painkillers among the consumers. For
this around 400 consumers as well as 100 chemists were
surveyed in Pune.

The key findings of the survey were astonishing as majority of

middle age people use these drugs irrespective of its side effects
and many of them consider it an easy way out to deal with pain
and avoid visiting a physician. Patients may also inadvertently take
multiple OTC drugs containing the same active ingredient, which
could lead to an overdose or increased side-effects. In other
cases, patients may take more than the recommended dose of a
drug, as they do not read or understand the directions or they
sometimes choose to ignore them, believing that a higher dose
should be more effective. The anomaly lies in the fact that it is the
educated and working class group of middle age taking these
steps. A majority of them are unacquainted with the names and
side effects of these drugs when not taken in a right fashion. They
tend to overlook the fact that the same drugs when used in the
correct manner would be much more beneficial.
RESULTS AND DISCUSSIONS
The average usage of painkillers age-wise was found to be as
represented in the chart below. Maximum consumption was found
to be amid the age group of 25 to 40 years. As revealed by the
survey this category resorts to self medication nearly 12 times in a
month. The most widely used painkillers were established as
paracetamol, nimusulide, diclofenac and ibuprofen.
Around 50% of the consumers surveyed did not consult any doctor
before using a painkiller. According to the chemists surveyed, 43%
of the consumers asked for painkillers without any prescription.
Also approximately 63% did not enquire about the side effects of
the medicine in question.
When enquired about the understanding of side-effects due to
painkillers, 36% were not aware of any while 46% of those
interviewed had heard of them but were not fully informed. Hardly
any consumers were disinclined to use painkillers due to their
side-effects.
SUGGESTIONS & RECOMMENDATIONS
Long term use of NSAIDs in high doses may cause an increased
risk of gastrointestinal complications ranging from stomach pain to
ulcers, hemorrhage etc. Thus an awareness regarding this has to
be created amongst the population as well as the physicians to
encourage the correct dosage and usage of the painkillers. For
this the followings steps can be taken:
1. Problems resulting from such inapt usage of OTCs should be
constantly highlighted in CMEs, journals, etc, so that the
physicians convey the same to those who do consult them before
using a NSAID. This population was found to be 23% of the
sample covered.
2. Since most of the NSAIDs are OTC drugs, it should be noted
that most chemists are ignorant about this and hence an attempt
should be made to educate the chemists regarding the adverse
effects of the same.
3. Education programs as well as workshops should be carried out
for the patients using painkillers to make them aware of the risks
associated with it.
4. In USA a campaign was carried out in 2003 known as
R.E.D.U.C.E (Risk Education to Decrease Ulcer Complications
and Their Effects from NSAIDs) by AGA (American
Gastroenterological Association), funded by Pfizer. Similar
campaign should also be initiated in India in cooperation with the
major Pharmaceutical companies.
5. Boards and Hoardings, highlighting serious complications
arising from unrestrained usage of NSAIDs, sponsored by
pharmaceutical organizations should be displayed in hospitals,
government dispensaries, and clinics of private practitioners.
6. Companies can also publish literature to inform laymen of the
right way to take these drugs in order to increase efficacy. As most
OTCs are mouth to mouth marketed, an initiative like this would
increase trust and loyalty in consumers and thereby increase
market potential.

Compiled by: Dipali Bobade, Nidhi Nirmal Rutuja Patil, Smita

Rathod, Soumya Gupta & Sourabh Dhopade (MBA-BT, Sem III )

Mentor: Pratiksha Singhal (alumnus MBA BT-2009 currently

working in WNS Global Services as Junior Analyst)

3
Pack in your senses
Packaging undoubtedly plays a critical role in any pharmaceutical
product, be it capsules, tablets, syrups or medical devices.
Products are packaged considering numerous factors such as
transit, weather, time and cost for maintaining their safety, stability
and integrity; long after they leave the manufacturing unit. It
provides companies one of the most important instruments for
their brand protection. In view of the fact that competition is
increasing day by day, companies constantly aim towards
differentiating their products to ensure consistency of growth.
Though highly significant pharmaceutical packaging in India
remained invariable but of late smart packaging and its direct
correlation with the product’s marketing is gaining importance in
this sector. A lot can be done in packaging in terms of the
positioning of a product, as it is the face of the brand. There are
also pass-offs which affect a brand. If there is a reputed brand
marketed in a particular category, then there are a host of brands
available which just mimic the packaging format or maybe the
color of the blister of that principle brand. One cannot identify
these from the original ones as they are genuine products coming
from companies with a proper manufacturing license. What these
companies try to do is ride on the brand image of the leader brand
that has been created over a number of years. This ends up
affecting the sales of the main brand tremendously. To avoid this,
companies can make provision for distinctive packaging in order to
gain an upper hand in the market.
Earlier the only function of packaging was to carry the product and
keep it safe until consumption. However of late it has been
observed by manufacturers that they can build credibility and the
user-product bond if consumers could 'SEE' the product. The
visual stimulus can never be ruled out, not at least for something
we ourselves consume. For instance transparent capsules with
colorful beads inside are not only attractive and appealing but also
more reliable. A syrup in a transparent glass bottle is preferred a
lot more than the amber color bottle. Transparent blister packs are
preferred more than the aluminum strips. As companies are
becoming more aware of this imperative fact, they are also
responding to the need and are no longer hiding medicines behind
opaque covers.
Another important aspect again revolving around visualization is
the color of the product. Color branding is very important, more so
for OTCs in India and across the globe. It is far more essential in
the developing and underdeveloped countries as people connect
to a product with its color and design in absence of formal
education. In fact OTCs and prescribed products should be
differentiated on grounds of packaging also and there should be a
clear demarcation among the two.
In OTC marketing, it is very vital that the patient gets the desired
effect the company is talking about. The information related should
be clearly written in the absence of a physician to provide the
guidelines. The enclosure should also contain a note explaining
the harmful effects of over-dosing and improper intake. For OTC
drugs, the packaging should establish a connection with the
consumer as in case of FMCG products. Any product intended for
child consumption will instantly reflect packaging content featuring
vibrant colors that appeal to the youngster’s mind. In International
market this scenario can be ordinarily experienced. For example,
an anti-AIDS pack was accompanied by a toothbrush to remind
the patient that the medicine had to be taken twice a day, like
brushing teeth.
4
There are different consumer conditions, different age groups or
lifestyle requirements that need different packaging solutions and
if these solutions are met effectively then it establish a sense of
commitment between the product and its consumer group. To
exemplify, arthritic patients have a set of requirements specific to
them which can be taken care of via some simple modifications in
packaging. Tylenol in USA launched a special yet simple pack for
arthritis patients. The toughest task for an arthritic is to open a lid
of the bottle containing medicine as they do not get enough grip to
turn open the lid. Tylenol launched a pack with a hole in cap. A
patient was expected to push a pencil in it and push it open. Such
endeavor not only makes things easy functionally for the patient
but also add to the goodwill of the company.
We can also observe utility of packaging of MWV Healthcare’s
‘Cerepak’. Its smart package is mainly used in clinical trials. It
records the date, time, and location of each tablet or pill as it is
removed from the package. This data can be quickly downloaded
into a computer for analysis by the patient or healthcare provider.
The system also enables interaction with the patient—it can record
side effects or symptoms, as well as discreetly prompt the patient
to take the medication using light, sound, or vibration.
In today’s era understanding the latent need of the consumer and
designing a product accordingly is what will help companies to go
the extra mile. For example, Diabetes sufferers who are on insulin
therapy at times need to carry the medication along with them
wherever they go. Thus Novo Nordisk's drug ‘Novopen’, when
launched, fulfilled this need perfectly as the pack looks just like a
pen and can be carried anywhere. Such packaging has the
additional potential to take away the stigma of a disease like
diabetes.
The other important factor which packaging deals with is
counterfeit drugs. Though pharmaceutical companies extensively
use holograms for this purpose but it has certain limitations.
Firstly, most of the patients lack the understanding or awareness
to look for a hologram and also it is practically impossible to create
awareness to see hologram of each drug before purchasing it.
Secondly, in some cases even holograms are copied. Thus in
such cases, color of the packaging also plays vital role in limiting
counterfeiting. If there is a product which has a unique color that
can't be copied it gets registered in the mind of the patient, then it
becomes a very strong feature with which a person can associate
and recognize the product when he goes to buy it. In addition to
this, pharmaceutical packaging must adhere to stringent
regulations that require material traceability, good manufacturing
practices (GMPs), consistent quality, product protection, and often
child-resistance. Pharmaceutical companies must therefore
consider their product on all such parameters and come up with an
“Optimal packaging complex” to utilize all advantages of effective
packaging.
Compiled by: Ashish Mishra (MBA- BT, Sem III)
Back to society- CSR initiative by
Torrent Group

Community welfare initiatives by any organization bring
about remarkable changes in the society and in the long
term prove to be a significant investment for the company
itself. One such initiative is undertaken by the Torrent
Group of companies, a multifaceted & dynamic group of
companies. The organization, one of its kind, strongly
believes that every bit of success should be shared with the
society that it exists in. To make a difference in the quality
of life at Ahmedabad & Surat in the areas of Health,
Education, Public Amenities and Community Development,
Torrent Group came out with a unique CSR initiative
‘SPARSH’.
Torrent promoted safe and efficient usage of electricity by
organizing exhibitions on electrical safety and general
safety, presenting the knowledge and requirements on
effective and safe usage of electricity at 3 schools in
Sabarmati for local residents and school students.
It also established and promoted institutions like U.N. Mehta
Institute of Cardiology and Research Centre at Ahmedabad.
The health check-up programmes organized in Schools of
torrent power AEC ltd aimed at strengthening the employee
employer relationship and promoted welfare of employee.

“Sparsh” is making a difference in improving quality of life in

slum areas by increasing the percentage of school going
children and spreading awareness about diseases and
education among them. This is very essential in a company
like India where a huge population resides in the slums and
most of children miss the basic amenities of life. Upgrading
of Municipal schools, Government hospitals and public
parks/gardens, beautification of the surroundings by
planting trees are among some of their CSR initiatives.

Health & Education: In 2005, 140 employees were

involved in an awareness program about education, health,
and hygiene though door to door canvassing; film shows,
putting up of posters and distribution of handbills, health
booklets in 3 major slums. Also Torrent provided teaching The tours organized for senior citizens to Torrent Power
aids in Urja Vidyalaya (school of Torrent Power AEC Ltd.) AEC Generation Plant at Sabarmati, built goodwill among
like creation of computer laboratory, assembly hall & senior citizens and made an impact about the company as
classroom. well.
Training programs for municipal school teachers were CSR initiatives are a very small step towards the strategic
organized with an objective to enhance the Primary School development of a company but a giant leap in improving the
Teachers teaching skills. life of people.
A health check-up camp was arranged for 641 students of
Urja Vidyalaya and 38 children residing in township were
examined by the Group doctors. Special Thanks to: Mr. Sandeep Yeshi & Mr. Gautam Bhatt
(Torrent Pharmaceuticals Ltd.)
In 2006, torrent initiated the up gradation of general medical
facilities in ESIS hospital and also renovated 5 municipal
Compiled by: Nivedita Singh & Snigdha Sinha (MBA-BT,
schools. Under "Jeevan No Ujaas" Program, slums in
Sabarmati area were 100% electrified. This was a real Sem III)
achievement as there are still many slums in other parts of
the nation who have not received a streak of electricity in
their entire existence.

COMMUNITY DEVELOPMENT & PUBLIC AMENITIES

Another aspect which the organization keeps in mind is

regarding A Swachchta Abhiyaan was undertaken to clean,
improve, and beautify roads and streets of Sabarmati. Also
it undertook an extensive task of cleaning of public water
storage tanks including 5 underground tanks.

In 2005 Torrent group also organized tours for members of

Senior Citizens Club to Torrent Power AEC Generation
Plant at Sabarmati, Torrent Power AEC Fly Ash Treatment
Pond, it also worked to enhance facilities for over 150
members of Senior Citizen's club including by providing
books to improve the quality of library.

5
 “Word-of-Mouth plays a vital
role….”
Mr. Madhukar Kurkoti has over 35
years of experience in the
Pharmaceutical Industry at senior levels
in diverse areas like strategic planning,
marketing, new product development,
company turnaround, and merger&
integration management. Some of the
companies he worked with are Torrent
Pharmaceuticals Limited, Reckitt Piramal
Limited, Nicholas Piramal India Limited
(NPIL), Redikure Medrox Nigeria Limited,
& Abbott Laboratories. Sir is associated as visiting faculty with
PUMBA for the MBA- BT program.
The PUMBA GAZETTE team managed to get an insight into the
OTC scenario in an exclusive interview with Sir.
Q1.What according to you is the drive for selecting an OTC
product?
Consumers are guided by various factors however the type of
consumer accounts for the major drive. Why people choose an OTC
product is different for the urban and for the rural areas.
In rural areas the issue is lack of access to a doctor and health
services in immediate vicinity. Besides most people do not pay
attention to minor ailments that may keep them away from farming or
any other money earning activity as there exists immediate need to
get back to work.
In the urban areas it is due to the busy lifestyle, which prevents people
from spending endless hours in a doctor’s clinic. In most cases the
initial demand is triggered by a doctor’s prescription. And then the
approach is generally ‘I have used this earlier for similar symptoms. I’d
therefore try it myself’. For minor ailments a friend’s advice is also
considered vary valuable. Word-of-Mouth plays a vital role.
Q2.What are the main promotional strategies adopted for OTC
products?
In addition to usual media like TV, Newspapers, Health Magazine
advertising companies use merchandising and trade promotion to
enhance revenues. Some companies use the packaging itself as the
silent seller.
Special in-store displays by the distributor’s salesmen are also
adopted by some companies.
The real key however is positioning. The same product can be
positioned as the first line of treatment, or the first line of defence or
the first step in prevention. Or, you could have a more serious
positioning ‘when every other remedy has failed’
Product differentiation is critical. The product has to work along all the
dimensions functionality, emotions and the social dimension.
Q3. Do companies opt for difference in marketing strategies of
OTC in developed developing and underdeveloped countries?
What are the major challenges faced?
The evolutionary stage of a market forces companies to adopt varying
strategies. It is also a function of the marketing environment,
regulatory challenges, sophistication and maturity levels of markets
and consumers. All these factors are further complicated by social
attitudes, work ethic and concept of urgency and time. Then there are
issues of logistics and economies of distribution penetration.
Packaging, unit-of –use, Cost per dose, money needed to be put down
also pose challenges.
In the advanced markets the battle is for shelf-space. In the developed
world there is the OTC expense being borne out-of-pocket and Health
insurance does not pick up the tab.
In the developing world the challenges is of spurious and ‘pass-off
‘products. In several developing markets home-remedies pose a
6
competitive challenge. For example in India more than 30 % of
consumers use a home remedies. This would also be true for other
countries with a well developed system of indigenous medicine e.g.
China, Indonesia, Sri Lanka etc.
Q4.What role does the pricing play with respect to OTC
products? Do companies prefer to adopt a competitive pricing
strategy?
All OTC products have to deliver on the value proposition first. Like
prescription products even for OTC products the truism “A product that
a cost more per unit is also the one that sells more units” will hold.
Pricing would be important in the context of the alternatives available
and the value being offered. In several cases need drives value. For a
person with a pounding headache, immediate relief is vital not the
price. Price in strategy terms has to be viewed as an integral part of
the total offering and brand experience rather than as a stand-alone
strategy.
The true differentiator for OTC products is the branding capability.
Q5.With increasing number of companies going global how do
they handle packaging related concerns? Is there any color
coding or font size guide followed?
Companies that operate globally ensure that they comply with the
regulatory and legal framework of every single country where they
operate. Labelling and packaging requirements are clearly stated for
most countries. For example all francophone countries mandate
companies to have a red box for prescription only schedule drug. In
India a product that has ingredients of animal origin need a brown box
with a brown dot.
In several countries a bi-lingual or a multi lingual packaging becomes
an imperative. One has also to keep the social meaning of color for
packaging design. The graphics used also have to be tested for any
adverse connotations. In terms of bar coding the universal packaging
code has to be followed.
Q6.China’s demand and the production for OTC has grown at a
fast pace in the last decade. Should India perceive China as a
potential threat to OTC market?
OTC business depends entirely on brand building capabilities. A
strong brand in China means nothing in the context of India. Brand
strengths are not transferable across borders. For example the brand
LIPOVITAN (A product containing Taurine, some B-Complex factors
and positioned as an energy drink) is a very powerful brand in Hong
Kong. In India it is REDBULL that has made an impact.
In addition the brand building capabilities of Indian companies are truly
world-class. The Chinese business model is based on economies of
scale, heavy subsidies, currency shoring efforts and not so much on
true entrepreneurial grit. Dr.MOM of Unique is one of the most
recognized brands in Russia.
Q7.It has been observed that there has been a serious misuse of
OTC products across India, Bangladesh, and Nepal in the past
few years. Is there a regulatory body to regulate such matters?
I remember there was an issue of misuse of a cough syrup brand few
years back. These things are generally triggered by an overzealous
sales person out for his performance bonus or an end user who has
found off-label use for a product.
The body to regulate these issues is the drug control authorities in
each country or in a given state. The issue revolves around an
inadequate administrative apparatus than an issue of political will.
Compiled by: The PUMBA GAZETTE Interview Team
Going Green-The Patent Way
The pharmaceutical industry channels an important proportion
of total research in most developed countries. Organizations
are driven to this field as medicines and their method of
production are commonly protected by patents. The huge
funds thus invested are only compensated for in the duration of
possession of patent. These patents remunerate a
researcher’s innovation stimulating further research and
development of medicines from which we all benefit.
However in recent years, pharmaceutical companies have
been accused of devoting their resources mainly to minor
improvements over existing medications. Globally, most MNCs
try to continuously extend their product patents by instituting
small chemistry-related changes. In trade circles this is known
as ‘Evergreening’. Evergreening is usually done to extend the
intellectual monopoly privileges, particularly over highly
profitable (either in total sales volume or price per unit)
“blockbuster” drugs.
In developing nations like India, such concepts would draw
multi facet reactions. It can lead to higher prices as companies
can charge whatever they wish due to their evergreen
monopoly over a patent. There are a large number of people
afflicted with cancer and HIV who need inexpensive medicines
to stay alive. Consequently in order to protect the interests of
the masses the Indian Patent Act does not allow Evergreening.
Section 3(d) of Indian Patent Act states that “The mere
discovery of a new form of a known substance which does not
result in the enhancement of the known efficacy of that
substance or the mere discovery of any new property or new
use for a known substance or of the mere use of a known
process, machine or apparatus unless such known process
results in a new product cannot be patented” It stipulated that if
a pharmaceutical company wanted a patent for an
improvement on an already existing drug, it must show that the
improvement actually made the drug more effective. However
logical it may seem, it is clearly not in the interests of the
multinational corporate lobby.
In the recent times, there is a section of the industry trying to
persuade the government to allow Evergreening. The issue is
whether it would be compatible with the World Trade
Organization’s Trade-Related Aspects of Intellectual Property
Rights (TRIPS) agreement to limit the grant of patents for
pharmaceutical substances to new chemical entities or new
medical entities involving one or more inventive steps only The
argument is that molecules are patented very early during the
process of drug discovery, but unique clinical characteristics or
benefits are not discovered until much later, when clinical trials
are conducted, if at all. Therefore, it is unreasonable to ask that
unique characteristics of a slightly altered molecule be
described at the time of the application for the patent, itself. A
government-appointed committee on patent laws, headed Dr.
R.A.Mashelkar, former chief of CSIR, favoured the grant of
patents to all incremental innovations made to a drug, but not
to light hearted Evergreening, in order to make the Indian
Patents Act TRIP’s compliant. Although the report ultimately
permitted most forms of Evergreening still the question
remains unanswered regarding the take on it.
7
Contrary to the claims by many drug companies increased
intellectual property protections have not fostered more
innovation for better treatment. Despite increased spending on
R & D over the past decade, the number of new drug
applications has not significantly increased. Further, 2/3rd of the
new drug applications are mere modifications to the existing
drugs. This process of making slight changes to drugs is often
used to prolong the life of patents in order to sustain
monopolies. With revenues exceeding $1 bn annually for many
drugs most pharmaceutical companies have been more
inclined to pour funds back into “blockbuster” drugs that can
yield further profits rather than more innovative treatments. So
having failed in the original attempt to prevent flexibilities being
incorporated in the TRIPS agreement, now the developed
countries under pressure from their pharmaceutical industry
lobby have turned their eye on World Intellectual Property
Organization (WIPO) to modify the original provision of TRIPS.
Ever greening, if permitted under Section 3(d) of the Indian
Patent Act then it would encourage renewal of patents and
block entry of low-priced generic drugs into the market. This
may prove to be a major setback to the Indian pharmaceutical
companies as a majority of their revenues come from generic
versions of patented drugs. It would also lead to a precipitous
rise in the prices of life-saving drugs and render them
inaccessible to the poor. To cite one instance, Leukaemia
patients could see the cost of their medication increase around
12 times.
On having a glimpse further the concept is not necessarily a
disadvantage to India. For example, if Evergreening is
permitted, Indian companies may be able to develop and
patent incremental advances on patented drugs and many new
drugs might enter the Indian markets. This could be aided by
the fact that working on already existent molecules is not as
difficult as stating a new molecule all together as it requires
less investment. Also there is immense scope in this field to
use Bioinformatics as companies can use molecular modelling
and drug designing principles to obtain better results. A de
novo drug would be difficult as compared to the betterment of
an existent molecule. At the same time the MNC’s would retain
the patent for the original drugs and earn huge profits which in
turn would be invested in the discovery of new molecules. This
would again open up scope for the generic companies down
the line and give them more business for the future. So in order
to ensure that people have access to medicines at affordable
prices what India needs to do is have laws that will increase
the benchmarks or threshold limits while granting patents
which is the ultimate purpose of Section 3(d) of Indian Patent
Act.
Compiled by: Nikhil Goyal, Vandita Javali.(MBA-BT, Sem III)
 PUMBA NEWS

I
t is with immense pleasure and pride that we inform Dr. B.V.
Sangvikar , Head , DMS( PUMBA) has been selected under
the exchange program “ Academic Mobility Program” at
Polytechno di Milano
University, Italy . This
program is undertaken by
the European Commission
“Erasmus Mundus” which
is a research collaboration
involving ten Universities
each from Europe and
India. Dr. Sangvikar’s area
of expertise is Retail
Management, and he is
among the chosen few to
be selected for this particular venture owing to his vast knowledge
and huge experience in the line. His forte would be on latest
trends in this field and he would be working with the Department of
Management & Industrial Economics of the University, Milan.

nother feather in the cap of Pumba’s achievement is that

A our Dean Dr.(Captain) C.M.Chitale has been appointed on

the executive body of
“YASHADA”
(Yashwantrao Chavan
Academy of Development
Administration) for 3 years.
Some of the objectives of the
academy as listed in the MoA
are to serve as an apex institute
for the collection and
dissemination of information
regarding development
administration and to provide
consultancy services in
development and public
administration. There are 8 members in the Committee who would
together be looking after the working of this body and Sir
represents the Pune region.

th

O
n July 18 PUMBA campus was graced by one of the most
eminent leaders of the Biotechnology Industry,
Dr.S.V.Kapre, Executive Director, Serum Institute of
India. He introduced the newly inducted students to the
highly potential Vaccine
Industry. Dr. Kapre talked
on the transition of the
Biotechnology Industry
throughout the years. He
emphasized on the role
played by Indian
companies in the global
Vaccine industry and
gave a brief introduction
to the general process
and financials of a
Vaccine launch. Last but
not the least, Dr. Kapre
enlightened the fresh minds of 2009-11 Batch and encouraged
them to excel in their future. An interactive session followed in
which Dr. Kapre answered the queries by students.